Optimizing the Delivery of Cancer Drugs that Block Angiogenesis

被引：58

作者：

Cao, Yihai ^{[1
]}

Langer, Robert ^{[2
]}

机构：

[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden

[2] MIT, Dept Chem Engn, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2010年 / 2卷 / 15期

关键词：

VASCULAR ENDOTHELIAL GROWTH; TUMOR ANGIOGENESIS; ANTIANGIOGENIC THERAPY; PDGF-BB; METASTASIS; NORMALIZATION; COMBINATION; BEVACIZUMAB; INHIBITOR; EFFICACY;

D O I：

10.1126/scitranslmed.3000399

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

Drugs that block angiogenesis are important components of first-line therapies for a number of human cancers. However, some of these agents have undesirable effects on the patient. Optimal delivery systems must be developed to maximize clinical benefits and minimize adverse effects in cancer patients. In this Perspective, we discuss these drug-related issues and propose ways to optimize antiangiogenic therapy by the development of new drug delivery systems.

引用

页数：5

共 47 条

[1]

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[2]

Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[3]

Molecular and cellular biomarkers for angiogenesis in clinical oncology [J].

Bertolini, Francesco ;

Mancuso, Patrizia ;

Shaked, Yuval ;

Kerbel, Robert S. .

DRUG DISCOVERY TODAY, 2007, 12 (19-20) :806-812

[4]

Browder T, 2000, CANCER RES, V60, P1878

[5]

Campbell RB, 2002, CANCER RES, V62, P6831

[6]

Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 [J].

Cao, RH ;

Bråkenhielm, E ;

Pawliuk, R ;

Wariaro, D ;

Post, MJ ;

Wahlberg, E ;

Leboulch, P ;

Cao, YH .

NATURE MEDICINE, 2003, 9 (05) :604-613

[7]

Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance [J].

Cao, Yihai ;

Zhong, Weide ;

Sun, Yan .

SEMINARS IN CANCER BIOLOGY, 2009, 19 (05) :338-343

[8]

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors [J].

Casanovas, O ;

Hicklin, DJ ;

Bergers, G ;

Hanahan, D .

CANCER CELL, 2005, 8 (04) :299-309

[9]

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer [J].

Dellapasqua, Silvia ;

Bertolini, Francesco ;

Bagnardi, Vincenzo ;

Campagnoli, Elisabetta ;

Scarano, Eloise ;

Torrisi, Rosalba ;

Shaked, Yuval ;

Mancuso, Patrizia ;

Goldhirsch, Aron ;

Rocca, Andrea ;

Pietri, Elisabetta ;

Colleoni, Marco .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) :4899-4905

[10]

Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis [J].

Dorrell, Michael I. ;

Aguilar, Edith ;

Scheppke, Lea ;

Barnett, Faith H. ;

Friedlander, Martin .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (03) :967-972

← 1 2 3 4 5 →